Chen et al. [108] prepared EGFR and CD44 dual-targeted HA NGs loaded with saporin (Sap-EGFR/CD44-NGs) for enhanced targetability with RIP activity for inhibiting metastatic 4T1 breast cancer in vivo. Here, EGFR is linked to breast cancer.